“I buy on the assumption that they could close the market the next day and not reopen it for five years.”
— Warren Buffett
A five-year holding period is a useful test of whether a stock has rewarded patient capital. For Idexx Laboratories, Inc. (NASD: IDXX), the result over the past five years was negative: a buy-and-hold investment initiated in September 2021 lost value by September 2026, with no dividend income to offset the share-price decline.
IDEXX is best known for veterinary diagnostics and software, and the stock has often traded at premium valuation multiples tied to expectations for durable growth. That context matters. When a company is priced for sustained expansion, even a high-quality business can produce weak shareholder returns if growth moderates, margins come under pressure, or the market simply assigns a lower multiple over time.
IDXX 5-Year Return Details
| Start date: | 09/13/2021 |
|
|||
| End date: | 09/10/2026 | ||||
| Start price/share: | $655.05 | ||||
| End price/share: | $506.53 | ||||
| Starting shares: | 15.27 | ||||
| Ending shares: | 15.27 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | -22.67% | ||||
| Average annual return: | -5.02% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $7,731.85 | ||||
What Happened to a $10,000 Investment in IDEXX?
A $10,000 investment in IDEXX Laboratories on 09/13/2021 would have declined to $7,731.85 as of 09/10/2026. Because IDEXX did not pay dividends during the period reflected here, the five-year total return was entirely driven by the movement in the share price.
In per-share terms, the stock fell from $655.05 to $506.53. That produced a cumulative loss of 22.67%, equivalent to an average annual return of -5.02%. The absence of dividend income is important: unlike income-producing equities, there was no cash yield or reinvestment effect to cushion the drawdown.
Key Takeaways From the 5-Year Holding Period
Share-price performance drove the entire outcome. With no dividends paid or reinvested, the ending value simply tracked the stock’s lower market price.
Entry valuation likely mattered. Buying a high-quality company at an elevated starting price can still lead to disappointing medium-term returns.
Business quality and stock returns are not identical. Strong underlying operations do not guarantee favorable shareholder results over a defined period, especially when expectations were already high.
Why a Strong Business Can Still Deliver Weak Stock Returns
For companies such as IDEXX, return outcomes are often shaped by three variables: revenue growth, profit conversion, and valuation multiple. If the business continues to expand but does so more slowly than investors once expected, the stock can decline even while fundamentals remain comparatively solid. Likewise, if interest rates rise or market preferences shift away from premium-multiple growth stocks, valuation compression can weigh heavily on returns.
This distinction is central to any buy-and-hold analysis. A five-year investment result does not by itself prove that the business weakened materially; it may instead indicate that the starting price embedded too much optimism. In practical terms, shareholders who purchased at a richer valuation in 2021 needed sufficiently strong earnings growth over the following years to justify that multiple. Based on the return data above, that support did not fully materialize in the stock price.
Bottom Line on IDEXX Stock’s 5-Year Return
The five-year buy-and-hold outcome for IDEXX Laboratories was unfavorable. An initial $10,000 investment fell to $7,731.85, for a total return of -22.67% and an annualized return of -5.02%. For investors evaluating IDEXX stock today, the period illustrates a familiar lesson: over multi-year horizons, the combination of business performance and starting valuation ultimately determines the return.
[These numbers were computed with the Dividend Channel DRIP Returns Calculator.]
More investment wisdom to ponder:
“You can’t be a good value investor without being an independent thinker; you’re seeing valuations that the market is not appreciating. But it’s critical that you understand why the market isn’t seeing the value you do.” — Joel Greenblatt
